Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

• Key market highlights

PART 05: Disease overview

• Pneumonia
• Types of pneumonia

PART 06: Market landscape

• Market overview
• Market size and forecast

PART 07: Pipeline analysis

PART 08: Market segmentation by drug class

• Antibacterial drug
• Antiviral drugs
• Others

PART 09: Geographical segmentation

• HAP drugs market in Americas
• HAP drugs market in EMEA
• HAP drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

• Market drivers
• Market challenges

PART 12: Market trends

• Combination therapy for the treatment of HAP
• Growing preference for accurate diagnosis of disease
• Rising R&D for effective treatment against superbugs/MDR microorganisms

PART 13: Vendor landscape

• Competitive landscape

PART 14: Key vendor analysis

• GlaxoSmithKline
• Merck
• Novartis
• Pfizer
• Other prominent vendors

PART 15: Appendix

• List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

• Manufacturers and suppliers
• Channel partners
• Industry experts
• Strategic decision makers

Secondary sources

• Industry journals and periodicals
• Government data
• Financial reports of key industry players
• Historical data
• Press releases

DATA ANALYSIS

Data Synthesis

• Collation of data
• Estimation of key figures
• Analysis of derived insights

Data Validation

• Triangulation with data models
• Reference against proprietary databases
• Corroboration with industry experts

REPORT WRITING